BD
BDSX.US Biodesix Inc
- Market cap
- USD 110M
- P/E
- -
- P/B
- 12.57x
- ROE
- -355.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BDSX.US undervalued?
Graham numberThe Graham number of Biodesix Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biodesix Inc fundamental analysis
No fundamental analysis for Biodesix Inc yet.
Biodesix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQL…
Full company profileBiodesix Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biodesix Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 20.4M | 24.6M | 45.6M | 54.5M | 38.2M | 49.1M | 71.3M | 88.5M | 102M |
| Gross Profit | 16.0M | 18.5M | 23.6M | 24.0M | 24.1M | 36.1M | 55.8M | 71.8M | 83.7M |
| Operating Income | -23.5M | -26.7M | -22.9M | -40.9M | -50.6M | -41.3M | -34.5M | -27.8M | -23.6M |
| EBITDA | -21.5M | -24.9M | -20.8M | -35.5M | -51.5M | -37.1M | -29.2M | -21.9M | -17.5M |
| Net Income | -26.2M | -30.7M | -31.4M | -43.2M | -65.4M | -52.1M | -42.9M | -35.3M | -30.8M |
| EPS | -20 | -23 | -24 | -32 | -31 | -13 | -6.62 | -4.67 | -2.89 |
| Balance Sheet | |||||||||
| Total Assets | 39.1M | 41.6M | 121M | 76.1M | 92.9M | 99.1M | 97.2M | 87.5M | 93.9M |
| Total Liabilities | 237M | 270M | 79.9M | 56.4M | 72.3M | 94.5M | 76.4M | 89.9M | 85.3M |
| Shareholders' Equity | -198M | -229M | 41.2M | 19.7M | 20.6M | 4.58M | 20.9M | -2.47M | 8.68M |
| Cash & Short-term Investments | 5.91M | 5.29M | 62.1M | 32.7M | 43.1M | 26.3M | 26.2M | 19.0M | 28.4M |
| Total Debt | 23.1M | 36.0M | 27.8M | 10.0M | 31.9M | 60.7M | 62.0M | 72.9M | 72.4M |
| Cash Flow | |||||||||
| Operating Cash Flow | -17.7M | -21.7M | -21.4M | -28.2M | -45.0M | -22.9M | -48.6M | -23.3M | -25.2M |
| Capital Expenditure | 617K | 1.31M | 2.18M | 2.55M | 3.53M | 23.1M | 3.23M | 403K | 1.11M |
| Free Cash Flow | -18.3M | -23.0M | -23.5M | -30.8M | -48.5M | -45.9M | -51.9M | -23.7M | -26.4M |
| Ratios | |||||||||
| ROE | - | - | -76.2% | -218.8% | -317.6% | -1,138.6% | -205.6% | - | -355.0% |
| ROA | -67.0% | -73.8% | -25.9% | -56.7% | -70.4% | -52.6% | -44.1% | -40.3% | -32.8% |
| Net Profit Margin | -128.1% | -125.1% | -68.8% | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% | -30.2% |
| Debt to Equity | - | - | 0.67x | 0.51x | 1.55x | 13.25x | 2.97x | - | 8.35x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biodesix Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 643K | 0.16 | - |
| 2022 | - | - | - |
| 2021 | USD 328K | 0.24 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Sep 15, 2025.
Who owns Biodesix Inc
- Insiders 38.20%
- Institutions 39.29%
- Public & others 22.51%
- Shares outstanding 11.1M
- Free float 5.51M
Top funds holding BDSX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| abrdn Healthcare Opportunities | 288K | 2.59% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 204K | 1.84% | 0.00% | Sep 2026 |
| 1290 Essex Small Cap Growth I | 59.3K | 0.53% | +0.53% | Sep 2026 |
| Fidelity Extended Market Index | 27.5K | 0.25% | -7.99% | Sep 2026 |
| iShares Micro-Cap ETF | 17.0K | 0.15% | 0.00% | Oct 2026 |
| Bridgeway Ultra-Small Company | 15.0K | 0.14% | 0.00% | Jun 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 12.5K | 0.11% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 11.3K | 0.10% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 9.64K | 0.09% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 4.51K | 0.04% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 3.53K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.65K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.50K | 0.02% | -62.84% | Aug 2026 |
| 1290 VT Micro Cap K | 1.16K | 0.01% | 0.00% | Sep 2026 |
| Victory Extended Market Index | 697.00 | 0.01% | +29.80% | Sep 2026 |
| Corgi Genomics & Precision Medicine ETF | 294.00 | 0.00% | 0.00% | Oct 2026 |
| JHVIT Total Stock Market Index I | 191.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding BDSX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AIGH Capital Management, LLC | 678K | 6.43% | -10.55% | Jun 2026 |
| Soleus Capital Management, L.P. | 586K | 5.55% | +40.65% | Jun 2026 |
| Telemark Asset Management, LLC | 490K | 4.64% | 0.00% | Jun 2026 |
| Aberdeen Group PLC | 389K | 3.68% | -15.23% | Jun 2026 |
| Vanguard Capital Management, LLC | 284K | 2.69% | +11.37% | Jun 2026 |
| Essex Investment Management Company, LLC | 242K | 2.29% | +83.15% | Jun 2026 |
| Opaleye Management Inc | 180K | 1.71% | -24.38% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 116K | 1.10% | -17.96% | Jun 2026 |
| Perceptive Advisors LLC | 109K | 1.03% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 91.5K | 0.87% | +238.52% | Jun 2026 |
| Two Sigma Investments LLC | 86.8K | 0.82% | +91.96% | Jun 2026 |
| Legato Capital Management LLC | 81.4K | 0.77% | +97.65% | Jun 2026 |
| Walleye Trading Advisors, LLC | 74.4K | 0.71% | +586.78% | Jun 2026 |
| StemPoint Capital LP | 70.0K | 0.66% | -50.00% | Jun 2026 |
| Geode Capital Management, LLC | 67.7K | 0.64% | +35.32% | Jun 2026 |
| Trexquant Investment LP | 58.0K | 0.55% | -16.71% | Jun 2026 |
| GSA Capital Partners LLP | 47.0K | 0.45% | +19.24% | Jun 2026 |
| Perkins Capital Management Inc | 44.6K | 0.42% | -0.37% | Jun 2026 |
| BlackRock Inc | 43.0K | 0.41% | +75.86% | Jun 2026 |
| Blair William & Co | 41.5K | 0.39% | +50.63% | Jun 2026 |
Biodesix Inc company profile
- Company name
- Biodesix Inc
- Ticker
- BDSX.US
- Exchange
- USA Stocks
- Listed since
- Oct 28, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 334
- Fiscal year end
- December
- Address
- 919 West Dillon Road, Louisville, CO, United States, 80027
- Phone
- 303 417 0500
- Website
- biodesix.com
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Biodesix Inc management
10- Mr. Scott HuttonPresident, CEO & Director · born 1972
- Ms. Robin Harper CowieCFO, Secretary & Treasurer · born 1980
- Dr. Heinrich Roder D.PhilFounder & CTO
- Dr. Gary Anthony Pestano Ph.D.Chief Scientific Officer · born 1968
- Ms. Jessica OlbrichtVice President of Human Resources
- Ms. Bobbi CoffinChief Growth Officer
- Dr. James R. Jett M.D.Co-Chief Medical Officer
- Dr. Steven C. Springmeyer FCCP, M.D.Co-Chief Medical Officer
- Dr. Michael N. Kammer Ph.D.Head of Radiomics
- Mr. Christopher VazquezVP & Controller